Recent Publications by Lilly: |
Attention deficit/hyperactivity disorder: burden of the disease according to subtypes in recently diagnosed children.
Introduction. Attention-Deficit/Hyperactivity Disorder (ADHD) is... | 3rd October, 2008
| Lilly Research Laboratories. Departamento Medico. Alcobendas (Madrid).
| Actas Esp Psiquiatr. 2008 Sep-Oct;36(5):285-94.
|
Cannabis and the Course of Schizophrenia.
Introduction. Attention-Deficit/Hyperactivity Disorder (ADHD) is... | 3rd October, 2008
| Dr. Zullino receives or has received research support from the Swiss
| Am J Psychiatry. 2008 Oct;165(10):1357-1358.
DOI Direct Link |
A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
PURPOSE: To determine the maximally tolerated dose (MTD) of biweekly... | 3rd October, 2008
| Authors' Affiliations: Memorial Sloan-Kettering Cancer Center, New York,
| Clin Cancer Res. 2008 Oct 1;14(19):6310-6.
DOI Direct Link |
Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.
Robust assessments of the nonclinical safety profile of biopharmaceuticals... | 30th September, 2008
| Eli Lilly and Company, DC 1940, Lilly Corporate Center, Indianapolis, IN
| Int J Toxicol. 2008 Jul-Aug;27(4):303-12.
DOI Direct Link |
Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa.
Hypothalamic nesfatin-1, derived from the nucleobindin2 (NUCB2) precursor,... | 27th September, 2008
| CURE/Digestive Diseases Research Center, Center for Neurobiology of
| Endocrinology. 2008 Sep 25.
DOI Direct Link |
AMPA receptor subunit-specific regulation by a distinct family of type II TARPs.
AMPA-type glutamate receptors (GluRs) play major roles in excitatory... | 27th September, 2008
| Department of Neuroscience, Eli Lilly and Company, Indianapolis, IN 46285,
| Neuron. 2008 Sep 25;59(6):986-96.
DOI Direct Link |
Allosteric modulation of NMDA receptor via elevation of brain glycine and d-serine: The therapeutic potentials for schizophrenia.
Ionotropic AMPA and NMDA glutamate receptors are ligand-gated ion channels... | 23rd September, 2008
| Neuroscience Discovery, Lilly Research Laboratories, Eli Lilly & Co.,
| Pharmacol Ther. 2008 Aug 27.
DOI Direct Link |
Bayesian adaptive non-inferiority with safety assessment: Retrospective case study to highlight potential benefits and limitations of the approach.
Adaptive trial design applied to randomized clinical trials of psychiatric... | 23rd September, 2008
| Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate
| J Psychiatr Res. 2008 Sep 17.
DOI Direct Link |
Role of metabotropic glutamate receptor 5 in the procholinergic effects of neuropsychotherapeutic compounds.
We investigated the participation of the metabotropic glutamate receptor... | 18th September, 2008
| Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
| Synapse. 2008 Sep 16;62(12):940-943.
DOI Direct Link |
Identification and characterization of an inhibitor specific to bacterial NAD(+)-dependent DNA ligases.
DNA ligases are the enzymes essential for DNA replication, repair and... | 18th September, 2008
| Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.
| FEBS J. 2008 Sep 13.
DOI Direct Link |
The temporal relationship between symptom change and treatment discontinuation in a pooled analysis of 4 schizophrenia trials.
Treatment discontinuation is common in antipsychotic trials for the... | 17th September, 2008
| Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN
| J Clin Psychopharmacol. 2008 Oct;28(5):544-9.
DOI Direct Link |
Exenatide pharmacokinetics in healthy Chinese subjects.
Objectives: Exenatide is an adjunctive treatment for Type 2 diabetes. This... | 17th September, 2008
| 1Peking University First Hospital, Beijing, People's Republic of China,
| Int J Clin Pharmacol Ther. 2008 Sep;Volume 46(September):459-465.
|
Weight management in a cohort of Irish inpatients with serious mental illness (SMI) using a modular behavioural programme. A preliminary service evaluation.
BACKGROUND: Weight gain is commonly observed during psychotropic... | 17th September, 2008
| Eli Lilly and Company Ltd, Adelaide Road, Dublin, Ireland.
| BMC Psychiatry. 2008 Sep 15;8:76.
DOI Direct Link |
A wellness intervention program for patients with mental illness: self-reported outcomes.
BACKGROUND: Weight gain is commonly observed during psychotropic... | 13th September, 2008
| Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
| Prim Care Companion J Clin Psychiatry. 2008;10(4):329-31.
|
The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials.
Background: Functional impairment is associated with major depressive... | 13th September, 2008
| Johns Hopkins University School of Medicine, Baltimore, Md. ; and Lilly
| Prim Care Companion J Clin Psychiatry. 2008;10(4):270-5.
|
